Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal
Alector’s approach combines an engineered GCase with the biotech’s blood-brain barrier delivery platform.
Alector’s approach combines an engineered GCase with the biotech’s blood-brain barrier delivery platform.